Loading
Give adjuvant treatment by the tumour's molecular class rather than by stage and grade: nothing for POLE-mutated, immunotherapy for MMRd, chemotherapy plus targeted agents for p53-abnormal, hormones for NSMP.
PORTEC-3 molecular analysis showed p53abn tumours gained the most from chemoradiation and POLEmut tumours nothing. The RAINBO programme (four parallel trials: p53abn-RED with olaparib, MMRd-GREEN with durvalumab, NSMP-ORANGE with progestin, POLEmut-BLUE de-escalation) and PORTEC-4a test this prospectively.
Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.
One of the most cited trial reports Europe PMC returns for Durvalumab in Endometrial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Durvalumab in Endometrial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Olaparib, Durvalumab.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer with no specific molecular profile, Endometrial cancer.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile, Endometrial cancer.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile, Endometrial cancer.
Shares Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), Endometrial cancer with no specific molecular profile, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer, Endometrial cancer.
Shares Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), PORTEC-3, POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.